Seroprevalence of human T-lymphotropic virus type I or II in sexually transmitted disease clinic patients in the USA.
cross_sectional · Level IV
Where this comes from
- Record sourced from PubMed, PMID 2192006.
- No licence information is recorded for this record.
- Because redistribution is not established, this page shows the abstract only. Follow the links below for the full text.
Abstract
Serum specimens from patients attending sexually transmitted disease (STD) clinics in Denver and several southeastern US cities were tested for antibody to human T-lymphotropic virus type I or II (HTLV-I/II). In Denver, 8 (2.1%) of 384 patients with a history of intravenous (IV) drug use, versus none of 201 non-IV-drug users, were HTLV-I/II seropositive. Only 2 (0.18%) of 1095 STD clinic patients from the southeastern USA had antibodies to HTLV-I/II. These data document a low prevalence of HTLV-I/II in STD clinic patients from the southeastern USA and confirm that IV drug use is an important risk factor for HTLV-I/II in the USA.
Medical subject headings
- HTLV-I Antibodies
- HTLV-I Infections
- HTLV-II Antibodies
- HTLV-II Infections
- Sexually Transmitted Diseases